AVUV vs XBI
Avantis US Small Cap Value ETF vs SPDR S&P Biotech ETF
- • AVUV has the lower expense ratio at 0.25% vs 0.35% for XBI.
- • AVUV pays a higher dividend yield (1.25%).
Side-by-side metrics
| Metric | AVUV | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.25% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.25% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $29.06B | $10.73B |
YTD return | 20.76% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.98 | 1.10 |
P/E ratio | 13.57 | — |
Last price | $123.50 | $164.01 |
Inception | — | — |
Issuer | Avantis | State Street |
AVUV top holdings
| VSAT | Viasat Inc | 1.39% |
| MATX | Matson Inc | 1.02% |
| LNTH | Lantheus Holdings Inc | 0.86% |
| IRDM | Iridium Communications Inc | 0.78% |
| AVT | Avnet Inc | 0.78% |
| M | Macy's Inc | 0.76% |
| LEA | Lear Corp | 0.75% |
| GATX | GATX Corp | 0.74% |
| AROC | Archrock Inc | 0.73% |
| CBT | Cabot Corp | 0.73% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About AVUV
AVUV (Avantis US Small Cap Value ETF) is US small-cap value with profitability screen. Managed by Avantis, the fund carries $29.1B in assets under management, an expense ratio of 0.25%, a dividend yield of 1.25%. Its largest holding is Viasat Inc (VSAT), which represents 1.4% of the portfolio. Real Estate is the fund's largest sector exposure at 0.7%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.